Immusoft
Immusoft Corporation is a biotechnology company focused on developing an autologous cell therapy platform aimed at treating a range of human diseases through its proprietary Immune System Programming (ISP) technology. Founded in 2009 and based in Seattle, Washington, Immusoft specializes in modifying the DNA of a patient's immune cells to create biofactories capable of producing gene-encoded medicines, including essential proteins and enzymes that may be missing or defective. The company's innovative approach involves reprogramming B cells, a type of immune cell, which enables them to manufacture and secrete various antibodies. This process not only provides a potential long-term solution for patients but also positions Immusoft at the forefront of biotechnology in addressing rare and infectious diseases.
Top Stages
1 past transactions
Discovery Genomics
Acquisition in 2016
Discovery Genomics, Inc. is an early-stage functional genomics company focused on discovering gene functions, validating drug targets, and designing therapeutic agents based on genomic information. The company holds exclusive licenses from the University of Minnesota for technologies related to "knock-downs" in Zebrafish, utilizing its proprietary Morphant technology, as well as the Sleeping Beauty Transposon. These technologies are instrumental in functional genomics and drug target discovery, with potential applications in gene therapy. The Morphant "knock-downs" enable the suppression and study of specific gene functions, while the Zebrafish model system offers a faster and more cost-effective method for gene discovery compared to other vertebrate models. As of March 2016, Discovery Genomics operates as a subsidiary of Immusoft Corporation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.